DUBLIN--(BUSINESS WIRE)--The 'Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030' report has been added to ResearchAndMarkets.com's offering.

都柏林--（商业新闻短讯）--“全球溶瘤病毒免疫治疗市场机遇与临床试验洞察2030”报告已添加到ResearchAndMarkets.com的产品中。

Currently, the US remains the market leader of the market as evident from rising collaborations, advancement and government bestow. The synergy between these clinical and commercial aspects propels the field forward, offering new expectation to cancer patients and shaping the future of cancer treatment.

目前，美国仍然是市场的领导者，这从不断增加的合作、进步和政府资助中可见一斑。这些临床和商业方面之间的协同作用推动了该领域的发展，为癌症患者提供了新的期望，并塑造了癌症治疗的未来。

Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy. As research further delves deeper into understanding the complexities of this innovative approach, there is optimism that oncolytic viruses will emerge as a valuable addition for cancer treatments, offering new avenues for improved outcomes and enhanced quality of life for patients..

持续的研究，创新和合作对于维持这种增长和实现溶瘤病毒免疫疗法的全部潜力至关重要。。。

Cancer endures to be a relentless adversary, challenging both patients and the medical community across the world. The quest of innovative and targeted therapies to battle against this multifaceted disease has led to remarkable advancements in the field of cancer therapy. Amidst the many emerging strategies, oncolytic virus immunotherapy has captured the attention of researchers and clinicians as a promising avenue for cancer treatment in the recent years.

癌症是一个无情的对手，挑战着世界各地的患者和医学界。寻求创新和有针对性的治疗方法来对抗这种多方面的疾病，已经在癌症治疗领域取得了显着进展。在许多新兴策略中，溶瘤病毒免疫疗法近年来引起了研究人员和临床医生的注意，成为癌症治疗的一种有前途的途径。

The realm of oncolytic virus immunotherapy harnesses the natural characteristics of viruses to selectively target and destroy cancer cells, offering a unique and precision oriented approach to treatment. As this therapeutic paradigm progresses from the realm of scientific discovery to commercial viability, it brings forth a multitudinous of opportunities and challenges that shape the dynamics of the commercial market..

溶瘤病毒免疫治疗领域利用病毒的自然特性选择性靶向和破坏癌细胞，提供独特且精确的治疗方法。随着这种治疗范式从科学发现领域发展到商业可行性，它带来了许多机遇和挑战，这些机遇和挑战塑造了商业市场的动态。。

Hitherto, 3 oncolytic virus immunotherapies, namely Oncorine (H101), Imlygic (Talimogene laherparepvec), and teserpaturev (G47?; Delytact), have been approved over the preceding decennium for the treatment of different types of cancer like head and neck cancer, melanoma and malignant glioma. However, it is expected that the domain will observe many more approvals in the upcoming years because of that fact that a handful of advanced oncolytic virus immunotherapies such as Oncos 102, CAN-2409, Pelareorep, CG070, VG161 have received designations like Fast Track, Orphan Drug, PRIME from regulatory agencies, FDA and EMA..

迄今为止，已经批准了3种溶瘤病毒免疫疗法，即Oncorine（H101），Imlygic（Talimogene laherparepvec）和teserpaturev（G47？；Delytact），用于治疗不同类型的癌症，如头颈癌，黑色素瘤和恶性胶质瘤。然而，预计该领域在未来几年将获得更多批准，因为少数先进的溶瘤病毒免疫疗法，如Oncos 102、CAN-2409、Pelareorep、CG070、VG161，已被监管机构、FDA和EMA指定为Fast Track、Orphan Drug、PRIME。。

In the clinical field, oncolytic viruses are at the forefront of innovative research and therapeutic development. These viruses, carefully engineered or selected for their innate oncolytic properties, are designed to infiltrate cancer cells, replicate within them, and induce their destruction while simultaneously stimulating an immune response.

在临床领域，溶瘤病毒处于创新研究和治疗开发的前沿。这些病毒因其先天的溶瘤特性而被精心设计或选择，旨在渗入癌细胞，在其中复制，并诱导其破坏，同时刺激免疫反应。

Moreover, as the sphere of oncolytic virus immunotherapy surpasses the confines of laboratories and clinical trials, its journey into the commercial arena is characterized by an involvement of pharma companies that will aid to shape its trajectory in the global cancer treatment landscape..

此外，由于溶瘤病毒免疫治疗领域超越了实验室和临床试验的范围，其进入商业领域的旅程的特点是制药公司的参与，这将有助于塑造其在全球癌症治疗领域的发展轨迹。。

The triumph of other immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, has generated considerable interest in harnessing the immune system to fight cancer. Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells.

其他免疫疗法的胜利，如检查点抑制剂和CAR-T细胞疗法，已经引起了人们对利用免疫系统对抗癌症的极大兴趣。溶瘤病毒免疫疗法通过利用病毒刺激针对癌细胞的免疫应答来补充这些方法。

The positive outcomes from these immunotherapies have fueled interest in leveraging the immune system to combat cancer, leading to increased exploration of oncolytic virus immunotherapy as a complementary and synergistic approach..

这些免疫疗法的积极成果激发了人们利用免疫系统对抗癌症的兴趣，从而增加了溶瘤病毒免疫疗法作为补充和协同方法的探索。。

On that account, multiple studies are ongoing in the clinical pipeline which comprise the combinations of oncolytic viruses with different types of antibodies targeting immune checkpoint receptors such as delolimogene mupadenorepvec with atezolizumab, OH2 injection, with or without irinotecan or HX008, ADV/HSV-tk with Pembrolizumab, for the treatment of patients suffering from wide array of cancer subtypes such as pancreatic cancer, Gastrointestinal Cancer, breast cancer etc..

因此，临床研究正在进行多项研究，包括溶瘤病毒与针对免疫检查点受体的不同类型抗体的组合，例如delolimogene mupadenorepvec与atezolizumab，OH2注射，有或没有伊立替康或HX008，ADV/HSV-tk与Pembrolizumab，用于治疗患有多种癌症亚型的患者，如胰腺癌，胃肠道癌，乳腺癌等。。

Competition from the involvement of multitudinous pharmaceutical companies such as Merck, Bristol-Myers Squibb, Astellas Pharma, Roche, Lokon Pharma, NRG oncology, CG oncology, Genemedicine, Binhui Biopharmaceutical Barinthus Biotherapeutics, TILT Biotherapeutics, Genelux Corporation, Replimune, and Candel Therapeutics have created wave in the commercial market of oncolytic virus immunotherapy.

来自默克（Merck），百时美施贵宝（Bristol-Myers Squibb），阿斯特拉斯制药（Astellas Pharma），罗氏（Roche），洛康制药（Lokon Pharma），NRG肿瘤学（NRG oncology），CG肿瘤学（CG oncology），基因医学（Genemedicine），宾辉生物制药（Binhui Biopharmaceutical Barinthus Biotherapeutics），TILT Biotherapeutics，Genelux Corporation，Replimune）和Candel Therapeutics等众多。

As a result, the clinical development landscape will observed several pharmaceuticals companies commencing research in order to understand the oncolytic virus mode of actions which will aid to develop advanced and innovative oncolytic virus immunotherapy with least possible side effects..

因此，临床开发前景将观察到几家制药公司开始研究，以了解溶瘤病毒的作用模式，这将有助于开发先进和创新的溶瘤病毒免疫疗法，尽可能减少副作用。。

It is projected that the market of oncolytic virus immunotherapy is poised to expand and multiply further in the forthcoming years due to the augmenting government regulatory approvals in conjugation with snow balling investments, collaborations and partnerships in the pharmaceutical sector. As of May 2024, the oncolytic virus is crowded by usage of different types of oncolytic virus like herpes simplex type-1 virus (HSV-1) or adenoviruses with or without chemotherapy, monoclonal antibodies directing against PD-1 and PD-L1 receptors, therapeutic peptide vaccines or nanoparticles in order to optimize delivery and performance for cancer treatments..

预计溶瘤病毒免疫疗法的市场将在未来几年进一步扩大和倍增，这是由于政府监管部门的批准增加，以及制药行业的滚雪球投资，合作和伙伴关系。截至2024年5月，溶瘤病毒因使用不同类型的溶瘤病毒而拥挤，如单纯疱疹病毒1型（HSV-1）或腺病毒，有或没有化疗，针对PD-1和PD-L1受体的单克隆抗体，治疗性肽疫苗或纳米粒子，以优化癌症治疗的递送和性能。。

Report Highlights:

报告亮点：

Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion by 2030

全球溶瘤病毒免疫治疗市场机会：到2030年超过15亿美元

Oncolytic Viruses Immunotherapies Clinical Trials by Company, Indication & Phase

溶瘤病毒免疫疗法临床试验（按公司、适应症和阶段）

Comprehensive Insight on Oncolytic Virus Immunotherapies in Clinical Trials: > 180 Therapies

在临床试验中全面了解溶瘤病毒免疫疗法：>180种疗法

FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME

FDA和EMA名称：突破疗法、快速通道、孤儿、优质

Patent Analysis Therapies in Clinical Trials

临床试验中的专利分析疗法

IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis

IMLYGIC，Oncorine，Delytact：可用性，剂量和价格分析

Platforms used for Developing Advanced Oncolytic Virus Immunotherapy

用于开发先进溶瘤病毒免疫疗法的平台

Key Topics Covered:

涵盖的关键主题：

1. Introduction to Oncolytic Virus Therapy

1、溶瘤病毒治疗简介

1.1 Overview

1.1概述

1.2 Need of Oncolytic Virus Immunotherapy

1.2溶瘤病毒免疫治疗的需求

2. Globally Approved Oncolytic Virus Immunotherapies

2、全球认可的溶瘤病毒免疫疗法

2.1 Commercially Approved Therapies

2.1商业批准的疗法

2.2 FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME

2.2 FDA和EMA名称：突破疗法、快速通道、孤儿、优质

3. Global Oncolytic Virus Immunotherapies Clinical Trials Overview

全球溶瘤病毒免疫疗法临床试验概述

3.1 By Phase

3.1按阶段

3.2 By Country

3.2按国家

3.3 By Company

3.3由公司提供

3.4 By Indication

3.4通过指示

3.5 By Priority Status

3.5按优先级状态

3.6 Patient Segment

3.6患者部分

4. Global Oncolytic Virus Immunotherapy Market Trend & Developments

4、全球溶瘤病毒免疫治疗市场趋势与发展

4.1 Current Market Outline

4.1当前市场概况

4.2 Future Market Forecast

4.2未来市场预测

5. Global Oncolytic Virus Immunotherapy Market Trends by Region

5、全球溶瘤病毒免疫治疗市场趋势（按地区）

5.1 South Korea

5.1韩国

5.2 Japan

5.2日本

5.3 US

5.3美国

5.4 Europe

5.4欧洲

5.5 UK

5.5英国

5.6 China

5.6中国

5.7 Australia

5.7澳大利亚

6. Global Oncolytic Virus Immunotherapy Market Trends by Indications

6、全球溶瘤病毒免疫治疗适应症市场趋势

6.1 Melanoma

6.1黑色素瘤

6.2 Head & Neck Cancer

6.2头颈部癌症

6.3 Glioma

6.3胶质瘤

6.4 Pancreatic Cancer

6.4胰腺癌

6.5 Ovarian Cancer

6.5卵巢癌

6.6 Lymphoma

6.7 Lung Cancer

6.7肺癌

6.8 Breast Cancer

6.8乳腺癌

6.9 Prostate Cancer

6.9前列腺癌

6.10 Hepatocellular carcinoma

6.10肝细胞癌

7. Global Oncolytic Viruses Immunotherapies Clinical Trials by Company, Indication & Phase

全球溶瘤病毒免疫疗法临床试验（按公司、适应症和阶段）

7.1 Research

7.1研究

7.2 Preclinical

7.2临床前

7.3 Phase-I

7.3第一阶段

7.4 Phase-I/II

7.4第一/第二阶段

7.5 Phase-II

7.5第二阶段

7.6 Phase-III

7.6第三阶段

7.7 Registered

7.7注册

8. Marketed Oncolytic Viruses Immunotherapies Clinical Insight

9. Global Oncolytic Virus Immunotherapy - Availability, Dosage & Price Analysis

全球溶瘤病毒免疫疗法-可用性、剂量和价格分析

9.1 Imlygic

9.1免疫

9.1.1 Overview & Patent Insights

9.1.1概述和专利见解

9.1.2 Pricing & Dosage

9.1.2定价和剂量

9.2 Oncorine (H101)

9.2 Oncorin（H101）

9.2.1 Overview

9.2.1概述

9.2.2 Pricing & Dosage

9.3 Delytact

9.3欺骗

9.3.1 Overview

9.3.1概述

9.3.2 Pricing & Dosage

10. Platforms used for Developing Advanced Oncolytic Virus Immunotherapy

用于开发先进溶瘤病毒免疫疗法的平台

10.1 KaliVir VET Backbone Technology

10.1 KaliVir VET主干技术

10.2 Calidi's Platform Technology

10.2 Calidi的平台技术

10.3 RenovoRx TAMP Platform

10.3 RenovoRx TAMP平台

10.4 ValoTx PeptiCRAd

10.4 Valotx Pepticrad

10.5 ValoTx PeptiVAX / PeptiENV / PeptiBAC

10.5 Valotx Peptivax/Peptienv/Peptibac

10.6 Transgene's Invir.IO Platform

10.6转基因的Invir。

10.7 Transgene's myvac Platform

10.7转基因的myvac平台

10.8 Imugene's CF33 Technology

10.8 Imugene的CF33技术

10.9 EpicentRx AdAPT Platform

10.9 EpicentRx自适应平台

10.10 Genelux's Choice Discovery Platform

10.10 Genelux的Choice发现平台

11. Oncolytic Virus Immunotherapy Combinations with Other Therapeutic Agents

溶瘤病毒免疫疗法与其他治疗剂的组合

11.1 Oncolytic Virus Immunotherapy with Nano materials

11.1纳米材料溶瘤病毒免疫治疗

11.2 Oncolytic Virus Immunotherapy with Chemotherapeutic Drugs

11.2用化疗药物进行溶瘤病毒免疫治疗

11.3 Oncolytic Virus Immunotherapy with Peptides

11.3用肽进行溶瘤病毒免疫治疗

11.4 Oncolytic Virus Immunotherapy with Targeted Immunotherapies

11.4溶瘤病毒免疫疗法与靶向免疫疗法

12. Global Oncolytic Virus Immunotherapy Market Dynamics

12、全球溶瘤病毒免疫治疗市场动态

12.1 Market Drivers

12.1市场驱动因素

12.2 Market Challenges

12.2市场挑战

13. Competitive Landscape

13、竞争格局

13.1 AdCure Bio

13.1 AdCure生物

13.2 Beijing SyngenTech

13.2北京先正达

13.3 BioVex Inc. (Amgen)

13.3 BioVex股份有限公司（安进）

13.4 Calidi Biotherapeutics

13.4卡利迪生物疗法

13.5 Genelux Corporation

13.5 Genelux公司

13.6 Immvira Pharma

13.6 Immvira制药公司

13.7 Jennerex Biotherapeutics

13.7 Jennerex生物疗法

13.8 KaliVir

13.8卡利维尔

13.9 Lokon Pharma

13.9乐康制药

13.10 Oncolys BioPharma

13.10 Oncoloys生物制药

13.11 PsiOxus Therapeutics (Akamis Bio)

13.11 PsiOxus Therapeutics（阿卡米斯生物）

13.12 Seneca Therapeutics

13.12塞内卡治疗学

13.13 Shanghai Sunway Biotech

13.13上海三威生物科技

13.14 Takara Bio

13.14高良生物

13.15 TILT Biotherapeutics

13.15 TILT生物疗法

13.16 Transgene

13.16转基因

13.17 Virogin Biotech

13.17 Virogin生物技术

For more information about this report visit https://www.researchandmarkets.com/r/8wp1iz

For more information about this report visit https://www.researchandmarkets.com/r/8wp1iz

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。